Travere: FILSPARI third-quarter sales climb about 120% year over year
FILSPARI sales reached $200.2 million in the third quarter, and management reaffirmed its $3 billion sales goal for 2033, per TradingView.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Travere Therapeutics (TVTX) reported third-quarter FILSPARI sales of $200.2 million, roughly 120% higher year over year, according to TradingView's summary of the update. Management kept its ambition of reaching $3 billion in sales by 2033.
On the pipeline, results from the HARMONY study are targeted for the second half of 2027, while an IND filing for civorebrutinib is expected by the end of the year.
why it matters
For investors, the key point is the rapid growth of an already marketed drug, which can help fund later-stage programs. Reaffirming the 2033 goal eases some doubts about strategy, but research timelines are still far off and delivery will depend on trial outcomes.
market impact
TVTX: strong FILSPARI sales support the stock as pipeline milestones move forward
- Travere shares (TVTX) pressure up — FILSPARI sales rose about 120% and the 2033 sales goal was reaffirmed
tags
instruments
sources
- TVTX: FILSPARI sales rose 120% YoY as pipeline programs advanced toward key milestones — TradingView, 2 November 2026 at 23:55 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗